AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 282: E1342-E1351, 2002. First published February 19, 2002; doi:10.1152/ajpendo.00564.2001
0193-1849/02 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/6/E1342    most recent
00564.2001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Larsen, M. O.
Right arrow Articles by Rolin, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Larsen, M. O.
Right arrow Articles by Rolin, B.
Vol. 282, Issue 6, E1342-E1351, June 2002

Mild streptozotocin diabetes in the Göttingen minipig. A novel model of moderate insulin deficiency and diabetes

Marianne O. Larsen1,4, Michael Wilken2, Carsten F. Gotfredsen3, Richard D. Carr1, Ove Svendsen4, and Bidda Rolin1

Departments of 1 Pharmacological Research I, 2 Assay and Cell Technology, and 3 Histology, Novo Nordisk, DK-2880 Bagsvaerd, Denmark; and 4 Department of Pharmacology and Pathobiology, Royal Veterinary and Agricultural University, DK-1870 Copenhagen, Denmark

Nonrodent models of diabetes are needed for practical and physiological reasons. Induction of mild insulin-deficient diabetes was investigated in male Göttingen minipigs by use of streptozotocin (STZ) alone (75, 100, and 125 mg/kg) or 125 mg/kg combined with pretreatment with nicotinamide (NIA; 0, 20, 67, 100, 150, and 230 mg/kg). Use of NIA resulted in a less steep slope of the regression line between fasting plasma glucose and changing doses compared with STZ [-7.0 ± 1.4 vs. 29.7 ± 7.0 mM · mg-1 · kg-1, P < 0.0001]. Intermediate NIA doses induced moderate changes of glucose tolerance [glucose area under the curve increased from 940 ± 175 to 1,598 ± 462 mM · min, P < 0.001 (100 mg/kg) and from 890 ± 109 to 1,669 ± 691 mM · min, P = 0.003 (67 mg/kg)] with reduced insulin secretion [1,248 ± 602 pM · min after 16 days and 1,566 ± 190 pM · min after 60 days vs. 3,251 ± 804 pM · min in normal animals (P < 0.001)] and beta -cell mass [5.5 ± 1.4 mg/kg after 27 days and 7.9 ± 4.1 mg/kg after 60 days vs. 17.7 ± 4.7 mg/kg in normal animals (P = 0.009)]. The combination of NIA and STZ provided a model characterized by fasting and especially postprandial hyperglycemia and reduced, but maintained, insulin secretion and beta -cell mass. This model holds promise as an important tool for studying the pathophysiology of diabetes and development of new pharmacological agents for treatment of the disease.

in vivo pharmacology; large-animal model; glucose tolerance; beta -cell reduction; glucose-stimulated insulin secretion.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. O. Larsen, B. Rolin, J. Sturis, M. Wilken, R. D. Carr, N. Porksen, and C. F. Gotfredsen
Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Gottingen minipigs in vivo
Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E670 - E677.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Pold, L. S. Jensen, N. Jessen, E. S. Buhl, O. Schmitz, A. Flyvbjerg, N. Fujii, L. J. Goodyear, C. F. Gotfredsen, C. L. Brand, et al.
Long-Term AICAR Administration and Exercise Prevents Diabetes in ZDF Rats
Diabetes, April 1, 2005; 54(4): 928 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. O. Larsen, C. B. Juhl, N. Porksen, C. F. Gotfredsen, R. D. Carr, U. Ribel, M. Wilken, and B. Rolin
{beta}-Cell function and islet morphology in normal, obese, and obese {beta}-cell mass-reduced Gottingen minipigs
Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E412 - E421.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. L. Brand, J. Sturis, C. F. Gotfredsen, J. Fleckner, C. Fledelius, B. F. Hansen, B. Andersen, J.-M. Ye, P. Sauerberg, and K. Wassermann
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats
Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E841 - E854.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. O. Larsen, B. Rolin, M. Wilken, R. D. Carr, and C. F. Gotfredsen
Measurements of Insulin Secretory Capacity and Glucose Tolerance to Predict Pancreatic {beta}-Cell Mass In Vivo in the Nicotinamide/Streptozotocin Gottingen Minipig, a Model of Moderate Insulin Deficiency and Diabetes
Diabetes, January 1, 2003; 52(1): 118 - 123.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Christoffersen, J. P. Goetze, E. D. Bartels, M. O. Larsen, U. Ribel, J. F. Rehfeld, B. Rolin, and L. B. Nielsen
Chamber-Dependent Expression of Brain Natriuretic Peptide and Its mRNA in Normal and Diabetic Pig Heart
Hypertension, July 1, 2002; 40(1): 54 - 60.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online